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Treatment of Basal Cell Carcinoma with Vismodegib
Sunitha Johns, Katlyn Brown, Emily Loudermilk, Crystal Zheng, Anh Dao Le, Sophocles Chrissobolis, Ph.D., assistant
professor of pharmacology

Abstract
The most prevalent nonmelanoma skin cancers are basal cell
carcinoma (BCC) and locally advanced basal cell carcinoma
(aBCC). Current, effective first-line treatments for BCC aim
to remove and destroy cancerous skin cells through excision
surgery, Mohs surgery, radiation therapy and cryotherapy,
while treatment of aBCC remains limited. An emerging treatment option for aBCC that promotes tumor size reduction is
vismodegib, a pharmaceutical product approved in 2012 by
the U.S. Food and Drug Administration (FDA). Vismodegib
was approved for the treatment of aBCC, metastasized HCC
(mBCC) or recurrent BCC after surgery as well as for use in
adults who are not candidates for surgery or radiation.
Vismodegib is an inhibitor of the hedgehog (Hh) pathway
·which is essential for cell differentiation and organ formation in embryonic development. When the Hh pathway is
inappropriately activated in tissues, Hh pathway cellular
growth mechanisms promote the formation of several carcinomas. Two studies reported similar responses of tumor
reduction to vismodegib in patients with aBCC and mBCC.
One reported the assessed response rate of 30 percent tumor shrinkage in patients with mBCC and a response rate of
43 percent tumor shrinkage in patients with aBCC. Another
reported objective responses in 46.4 percent of aBCC and
30.8 percent in mBCC. While vismodegib is an option for
treatment, caution should be used. Pharmacists play a criti.cal role by counseling on proper skin care, potential drug
interactions and the different side effects of treatment
Vismodegib should be continuously studied as there is currently not enough information on long-term treatment opt_i_!>_ns for I!~!!!:_f!~:
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Introduction
In the United States, about 3.3 million people are diagnosed
with nonmelanoma skin cancers each year, causing skin cancer to be the most common type of cancer.1 Over the past
two decades, the rate of diagnosis and treatment for nonmelanoma skin cancers has increased 77 percent, with
women under the age of 40 years being a fast growing, atrisk population.2 Basal cell carcinoma (BCC) is characterized
by the growth of cancerous cells located in the lower epidermis. Although BCC has a lower mortality rate in comparison
to its counterpart, melanoma, BCC is the most prevalent
nonmelanoma skin cancer and comprises 80 percent of all
skin cancers.3 About 2,000 people die from BCC and squamous cell carcinoma each year; in comparison, an estimated
10,130 people will die from melanoma in 2016. 1.3 However,
BCC deaths rates are best depicted as estimates since it is
Winter 2017 Volume 8, Issue 1

not required to report BCC or squamous skin cell carcinomas to cancer registries. When BCC is not treated effectively
or in a timely manner, progression of the disease can result
in local tissue invasion and significant morbidity and mortality.4
Basal cell carcinoma presents as nonpainful red patches or
shiny bumps on the skin of the head and neck. Risk factors
for BCC include sun and radiation exposure, elderly age,
light-colored skin and extended exposure to certain chemicals such as coal and tar as well as arsenic found in well waters and pesticides.1-3 Current, effective first-line treatments
aim to eradicate and destroy cancerous skin cells through
excision surgery, Mohs surgery, radiation therapy and cryotherapy.4 Treatment options depend on tumor size and location as well as disease progression. Large tumors located on
the face, fingers and genital areas have a better cure rate
when treated with Mohs surgery, a complex but effective
surgical option. When BCC progresses to invade significant
local tissue, health care costs increase because treatment
requires specialized surgical teams, postoperative hospital
stays and expensive pharmacologic options.2 From 2005 to
2008, nonmelanoma skin cancer accounted for 4.5 percent
of Medicare expenses making it the fifth most costly cancer
to treat. Although the incidence rate of locally advanced BCC
(aBCC) is hard to determine due to lack of standardized
staging systems and lack of uniform reporting requirements,
it has been speculated that aBCC comprises roughly 1 to 10
percent of BCC. In rare cases where the cancer advances beyond its initial site, surgery is not recommended due to potential risks for surgical disfigurement and tissue damage,
depending on the extent of tissue invasion. An emerging
treatment option for aBCC is vismodegib, a pharmaceutical
product approved in 2012 by the FDA which promotes tumor size reduction through its inhibitory action on the
hedgehog (Hh) pathway. 4 This article will discuss the Hh
pathway, the pharmacology of vismodegib, research studies
supporting its clinical use and the role of the pharmacist in
monitoring vismodegib therapy.

The Hedgehog Pathway
The Hh pathway is essential for cell differentiation and organ formation in embryonic developments The Hh pathway
is normally suppressed in adult tissues; however, when it is
inappropriately activated, Hh pathway cellular growth
mechanisms promote the formation of several carcinomas.
The Hh pathway was first discovered in 1980 when researchers learned of gene mutations that caused deformed
bodies in fruit flies. Mutation to the Drosophilia hedgehog
gene resulted in the formation of the mutated polypeptide
ligand (Hh ligand) which activated the abnormal Hedgehog
pathway. It was subsequently reported that the gene muta-
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tions were involved in early embryonic development which
linked the pathway to several cancers.s.6

it SMO signal transduction, and thus inhibit GLI oncogene
transcription (Figure la).s

The first molecule developed to inhibit the Hh pathway was
cyclopamine, a teratogen isolated from corn lilies.s This naturally derived product was found to bind and inhibit Smoothened (SMO), a seven-member transmembrane protein resembling a G-protein coupled receptor. By inhibiting SMO
signal transduction, cyclopamine inhibits the activation of
GLI, a protein first isolated in human glioblastoma which is
also an oncogene transcriptional activator. GLI has multiple
actions: it mediates cell proliferation, causes upregulation of
antiapoptotic proteins, causes down-regulation of apoptotic
proteins, increases production of vascular endothelial
growth factor (VEGF) and angiogenesis factors and decreases
E-cadherin and tight junctions holding the epithelial cells
together.s.7 Thus, inhibition of SMO by cyclopamine inhibits
transcriptional responses of GLI, ultimately inhibiting tumor
formation. As an endogenous natural defense against tumor
formation, patched-1 (PTCH-1), a 12-member transmembrane protein receptor, suppresses SMO and prevents downstream activation of the Hh pathway. Abnormal reactivation
of the Hh pathway occurs when a mutated PTCH-1 is unable
to suppress SMO, or when the Hh ligand binds to and inactivates PTCH-1. allowing for SMO to activate tumorigenesis. 5
Vismodegib was developed as a cyclopamine analog to inhib-

Vismodegib Pharmacology
Mechanisms of Action, Uses, Pharmacokinetics and Cost
Vismodegib (Erivedge® Capsule, Figure lbB) was developed
by Genentech, Inc. as the first selective Hh pathway inhibitor
which had a higher affinity for SMO and improved pharmacokinetic properties compared to cyclopamine.s The FDA
approved vismodegib in January 2012 in adults for the treatment of the following: local aBCC, metastasized BCC (mBCC),
recurrent BCC and recurrent aBCC following surgery.
Vismodegib is also indicated to treat BCC patients who are
not candidates for surgery or radiation.7 The National
Comprehensive Cancer Network guidelines for basal cell skin
cancer list vismodegib as an option for high-risk patients.9
Patients may be classified as "high-risk" if they are immunosuppressed. Basal cell carcinoma may also be deemed
high-risk ifthe skin lesions are recurrent, have badly defined
borders or have an aggressive growth pattern. Vismodegib
and other Hh pathway inhibitors are limited to use in highrisk cases most likely due to the resistance potential and the
known fertility issues.

Figure 1. The Hedgehog (Hh) Pathway.a
The Hedgehog (Hh) pathway, which is normally suppressed in adults, is reactivated in BCC to promote tumorigenesis.
In healthy individuals, patched-1 (PTCHl) inhibits signal transduction of Smoothened (SMO). In cancer patients, PTCHl is
mutated or is suppressed by the Hedgehog ligand (represented as a red hexagon in Figure la), and SMO is fully functional to
cause the activation of oncogene transcription activator, GLI. Vismodegib inhibits SMO to prevent GLI activation. As a result,
vismodegib inhibits cell proliferation, apoptosis and angiogenesis mediated by GLI.
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Vismodegib is available as 150 mg capsules taken orally daily
for 28 days or until remission. 10 Vismodegib can be taken
with or without food. Additional pharmacokinetic properties
ofvismodegib are presented in Table 1. The cost for a 28-day
supply of vismodegib is $12,305.52. Vismodegib is available
in the United States at specialty pharmacies through the Erivedge Access Solution program.
Adverse Effects, Warnings and Drug Interactions
Side effects (with incidence rate in parentheses) of vismodegib include: nausea (30 percent), diarrhea (29 percent),
fatigue (40 percent), weight loss (45 percent), dysgeusia (SS
percent), muscle spasms (72 percent), amenorrhea (30 percent) and alopecia (64 percent).11 Vismodegib should be
avoided in patients who have concerns about hair loss, who
operate machinery and require full muscle functionality and
in women who have irregular menstrual cycles. Cyclobenzaprine administration is recommended when patients experience drug-related muscle spasms. 2 To relieve nausea and
poor oral intake, dronabinol and megestrol acetate have
been used, respectively.
There are no contraindications on the manufacturer's labeling, but use in pregnant women (Pregnancy Category D) or
women who are breastfeeding is strongly discouraged.lo
Vismodegib can cause severe birth defects and embryo-fetal
death, so pregnancy status needs to be verified prior to
starting vismodegib therapy.12 During an in vivo study in
pregnant rats, vismodegib caused craniofacial abnormalities,
anorectal defects and absent or fused digits in hindlimbs,13
Therefore, it is recommended that patients and their partners use two forms of medically reliable birth control to
avoid pregnancy during vismodegib therapy.7 Vismodegib is
also present in the semen, so it is important to advise male
patients to avoid donating semen during therapy and for
three months after the final dose of vismodegib. Men should
also be counseled to use condoms while he or his male or
female partner is on treatment.6 In addition, since women
have a risk of developing amenorrhea while on vismodegib
(33 percent of patients), it is important to counsel on poten-
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tial infertility. 12 Patients should also be advised not to donate
blood or blood products during therapy and within seven
months after the end of treatment.6
Since vismodegib is a substrate for p-glycoproteins, coadministration with p-glycoprotein inhibitors such as
azithromycin, clarithromycin and erythromycin may increase blood concentrations of vismodegib and thus increase
risk of side effects. 5 Drugs that alter the pH of the upper gastrointestinal tract such as proton pump inhibitors, histamine
2-receptor antagonists and antacids may affect the solubility
of vismodegib and reduce its bioavailability. In addition, patients taking vismodegib concurrently with warfarin should
be monitored for elevation in international normalized ratio
(INR) and signs of bleeding as the high protein binding ability of vismodegib can displace warfarin from plasma proteins.12 A specific example of the interaction of vismodegib
with warfarin was detailed in a case study published in the
American Journal of Health-System Pharmacists.14 One patient who had been well controlled on warfarin for nine
months prior to vismodegib therapy had supratherapeutic
INR levels of 4.6, 9.5 and 9.3 after starting vismodegib. Other
causes of the INR increase such as change in diet, alcohol or
cigarette use, medications and acute illness were ruled out,
so the vismodegib-warforin drug interaction was deemed to
be the probable cause of the increase in INR. Anticoagulation
therapy may be necessary in vismodegib patients due to the
increased risk of venous thromboembolism that occurs in
malignancy. However, an alternative prophylaxis medication
may be required in place of warfarin if adequate INR control
cannot be maintained in patients taking concurrent warfarin
and vismodegib.
Efficacy and Safety
Two important studies evaluated the efficacy and safety of
vismodegib. In the first study, Sekulic et al. conducted an experiment which involved two cohorts with the goal of measuring the efficacy and safety ofvismodegib.lSThere were 104
participants enrolled in the study over 13 months at 31 sites
in the United States, Europe and Australia. The study began
on Feb. 10, 2009, and was concluded nine months after the

Table 1. Pharmacokinetics ofVismodegib.s,10

Absorption

Highly permeable with low aqueous solubility (Biopharmaceutical Classification System Class II)
Bioavailability 32%

Distribution

V d =16.4-26.6 L
Plasma protein binding > 99%, primarily to albumin and alpha1 acid glycoprotein (AAG)

Metabolism

Oxidation, glucuronidation, pyrimidine ring cleavage carried out by CYP2C9, CYP3A4, CYP3AS
enzymes; P.::glycoproteins promote efflux of drug

Excretion

Hepatic (82% of administered dose found in feces)
Renal (4.4% of administered dose found in urine)
Elimination t1;2: 4 days (for continuous once daily dosing) and 12 days (after single dose)
No hepatic or renal dosing adjustments
Winter 2017 Volume 8, Issue 1

THE PHARMACY AND WELLNESS REVIEW

19

Dermatology

Treatment of Basal Cell Carcinoma with Vismodegih

first treatment of the last enrolled patient on Nov. 26, 2010.
Vismodegib was given until there was disease progression,
unacceptable toxic effects or the discontinuation of the study.
The primary endpoint was the objective response rate, and
the primary hypotheses were that the response rate would
be greater than 20 percent for patients with locally aBCC and
greater than 10 percent for those with mBCC. For the primary endpoint, response evaluation criteria in solid tumors
(RECIST) guidelines were used. This set of guidelines
measures tumor shrinkage along with the development of
disease progression (defined as an increase in tumor size of
20 percent or more) or regression (defined as a decrease in
tumor size of 30 percent or more).
Due to the small patient population and lack of effective therapeutic options, there was no control group in the study.is
Patients were divided into two cohorts: 33 patients had
mBCC and 71 had local aBCC. Each patient was given 150 mg
vismodegib once daily. Patients received physical examination and lab testing every four weeks (including pregnancy
testing for women of childbearing potential). All patients
with radiographically measurable disease received a radiographic assessment of tumors, performed at baseline and
every eight weeks thereafter. Both cohorts experienced a
significant reduction in tumor size: 30 percent reduction in
patients with mBCC (p < 0.001) and 43 percent reduction in
patients with aBCC (p < 0.001). Furthermore, 64 percent of
mBCC patients and 38 percent of aBCC patients were considered to have stable disease after treatment with vismodegib.
Of the 63 patients included in the trial, 21 percent had a complete response (defined as the absence of residual metastatic
growth of BCC on assessment of a biopsy specimen). At the
end of data collection, 77 percent of patients who had a complete response had not experienced disease progression.
Overall results showed that the majority of patients within
the study experienced tumor shrinkage. Adverse effects were
reported by all patients during the study, but more than half
of the patients (5 7 percent) experienced only mild or moderate effects. Common adverse effects included muscle spasms,
alopecia, dysgeusia, weight loss, fatigue, nausea, decrease in
appetite and diarrhea. Fatal adverse events were reported in
6. 7 percent of patients.
A study by Chang et el. assessed efficacy and safety of vismodegib in patients in an open-label multicenter study with two
cohorts: local aBCC and mBCC. 16 The study population consisted of 120 patients; 62 in the aBCC cohort and 58 in the
mBCC cohort. However, only 119 patients were considered
safety-evaluable, of which 95 were considered efficacyevaluable. Patients included in the study had to be at least 18
years of age with good organ function and having measurable disease state based on RECIST version 1.0 guidelines.
Exclusion criteria included major organ dysfunction, pregnant or lactating mothers, women unwilling to practice birth
control, completion of antitumor therapy less than 21 days
before treatment initiation, a history of other diseases or
uncontrolled medical conditions, or those who had less than
12 weeks of life expectancy. Patients received 150 mg of
vismodegib daily until either the disease progressed or there
was intolerable toxicity. Tumors were assessed with the RE-
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CIST guidelines. One treatment cycle was defined as 28 days,
and patients were physically assessed every one to two treatment cycles. Patient assessment parameters included complete blood cell count, metabolic panel and adverse
event recordings.
Within the patient population, 56 patients with local aBCC
and 39 patients with mBCC were evaluated for efficacy.16
Objective tumor responses of 46.4 percent and 30.8 percent
were met by local aBCC and mBCC patients, respectively. Objective tumor responses, defined as the best overall complete
response or partial response, were confirmed by investigators using two consecutive tumor assessments performed at
least four weeks apart according to RECIST version 1.0. Complete response was achieved in 8.4 percent of total patients,
partial response was seen in 31.6 percent of total patients
and 49.S percent of all study patients experienced stable disease. Overall, 94.6 percent patients in the local aBCC cohort
and 82.1 percent patients in the mBCC cohort had complete
response, partial response or stable disease. Only three patients with mBCC exhibited progressive disease, whereas no
patient within the local aBCC cohort experienced progressive
disease.
Almost all safety-evaluable patients experienced a treatment
emergent adverse event, typically within grades 1 and 2. A
grade 1 adverse event is characterized by mild symptoms or
no symptoms, while a grade 2 adverse event is defined as
showing moderate symptoms requiring minimal, local, noninvasive intervention.17 The majority of adverse events, including muscle spasms, dysgeusia, alopecia, diarrhea, nausea,
fatigue and weight loss, were mild to moderate and occurred
within the first seven treatment cycles.16 Grade 3 adverse
events were seen in 24 patients, meaning that the patients
experienced severe or medically significant but not immediately life-threatening effects. The only vismodegib-related
serious adverse event reported was muscle spasm, seen in
1 percent of the population. Grade 4 responses, defined as
life-threatening events requiring immediate care, were seen
in nine patients. 16,l7 These included diarrhea and muscle
spasms. Only two patients experienced a grade 5 adverse
event, which resulted in death. All deaths were considered
due to disease progression and not treatment related.
Overall, both studies showed similar responses to vismodegib in patients with local aBCC and mBcc.1s,16 This medication
should be continuously studied, as there is not extensive information available regarding long-term vismodegib treatment. Vismodegib is FDA-approved for use in adults but has
yet to be examined in children. Clinical trials examining the
efficacy and safety of vismodegib in larger patient populations are currently underway.

Clinical Relevance and the Pharmacist's Role
As one of the most accessible health care providers, pharmacists can play an important role in vismodegib therapy. In
addition to answering questions patients may have about the
drug or drug therapy, pharmacists can also counsel on the
importance of proper skin care.rn Simple steps such as wearing a hat, wearing sunscreen with both ultraviolet A and ul-
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traviolet B protection and limiting exposure during midday
when the sun is at its strongest can help to prevent new or
worsening skin cancer. Pharmacists can also assist with monitoring the color, size, border and symmetry of moles.
As previously mentioned, it is critical that patients use proper pregnancy prevention while taking vismodegib and for a
period after vismodegib is discontinued (seven months for
women and three months for men). 19 Pharmacists should
remind both male and female patients of the teratogenicity
risks associated with vismodegib and aid in selection of birth
control methods. Vismodegib has been shown in animal
models to have a potential for irreversible infertility which
may be problematic for patients of childbearing age. 2 0 It may
be necessary to explore other drug options if a patient desires to expand his or her family. Pharmacists are wellpositioned and qualified to aid patients in creating reproductive life plans and selecting the best birth control methods to
fit the patient's lifestyle. Furthermore, pharmacists can make
referrals for counseling or other services that would benefit
patients. Importantly, pharmacists can also play a part in
helping minimize drug interactions. This is particularly true
for the interaction between vismodegib and warfarin, especially as pharmacist-run anticoagulation clinics become more
prominent.
Since vismodegib is a specialty drug (a drug that is unable to
be dispensed at a community pharmacy due to side effects or
increased complexity of administration, handling or billing),21 pharmacists may not be included in every step of the
billing process. Billing may be conducted by a specialty pharmacy division which handles prior authorizations and other
steps necessary to get the medication covered by insurance.
If a patient needs further financial assistance, he or she can
be directed to the manufacturer's website, www.erivedge.
com.19 In the website's financial support section, there are
four simple questions to determine if the patient is eligible
for a co-pay card from Genentech. The site also contains valuable information including tips for managing side effects,
frequently asked questions and support for patients and
health care professionals.
Conclusion
Overall, vismodegib therapy should be considered as an option for high-risk aBCC and mBCC patients who can be monitored monthly. Most patients have experienced stabilization
or resolution of disease with this drug while experiencing
only mild or moderate side effects. Still, monitoring of tumor
size is important since there is resistance potential, which
could lead to treatment failure. While vismodegib has shown
benefits in patients being treated for local aBCC and mBCC,
use of this drug in patients with a desire to start or expand a
family should be done with extreme caution due to the importance of the Hh pathway in fetal development.
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